IFLR1000

Search results

Narrow your search

Result types
Article type
Jurisdiction
Practice area
Industry sector
Bar admission

Showing 6651 - 6660 of 11100 for "Private equity" with applied filters

News & Analysis

Hong Kong: Stock Exchange Conclusions on Corporate Governance Code

06 January 2022 by LC Lawyers

The Stock Exchange of Hong Kong Limited (“Stock Exchange”) published in December 2021 the conclusions to its consultation paper of April 2021 titled “Review of Corporate Governance Code and Related Listing Rules”, with an aim to enhance the corporate governance practices and reporting by listed companies.
News & Analysis

Integrity is key: Hong Kong’s new Corporate Governance Code mandates that issuers establish anti-corruption and whistleblowing policies

04 January 2022 by LC Lawyers

In our earlier publication “COVID-19 heightened corruption risks – A Hong Kong guide”1, we forewarned that COVID-19 and the challenges it posed to enforcement authorities, organizations and their workforce would allow corruption to thrive.

News & Analysis

Romania: RTPR advises Meridiam on acquisition of a shareholding stake in Netcity

24 December 2021 by Radu Tărăcilă Pădurari Retevoescu - Allen & Overy

RTPR has provided legal advice to Meridiam SAS in relation to entering Netcity Telecom’s shareholding, the company that operates the underground telecommunications infrastructure in Bucharest.

News & Analysis

Mexico: New partners announcement

22 December 2021 by Ritch Mueller y Nicolau

We are pleased to announce the following lawyers as new partners of our firm
News & Analysis

Switzerland: MLL strengthens its Competition, Corporate and M&A and China Desk competencies with the appointment of Renato Bucher, Florian Müller and Christian Rebell to the MLL partnership

16 December 2021 by MLL Meyerlustenberger Lachenal Froriep

MLL is delighted to announce that Renato Bucher, Florian Müller and Christian Rebell will become partners of the firm on 1 January 2022.
News & Analysis

New successful business combination for Luxembourg-incorporated and Frankfurt listed SPAC

14 December 2021 by Arendt & Medernach

Arendt advised 468 SPAC I SE, a Luxembourg special purpose acquisition company (SPAC) sponsored by Alexander Kudlich, former Rocket Internet board member, Ludwig Ensthaler and Florian Leibert, in its successful business combination with Boxine GmbH ("Boxine")
News & Analysis

Romania: NNDKP assists Safety Broker in the sale of an 80% stake to Unilink

13 December 2021 by Nestor Nestor Diculescu Kingston Petersen

NNDKP has assisted Safety Broker, the largest independent insurance broker operating in Romania and in the Republic of Moldova, in the sale of 80% of the company’s shares to the Unilink group, leader on the relevant Polish market.
News & Analysis

Luxembourg: Stéphanie Lhomme joins Arendt Regulatory & Consulting to enrich Arendt’s financial crime and forensic investigations offering

30 November 2021 by Arendt & Medernach

Stéphanie Lhomme has joined Arendt Regulatory & Consulting in the role of Director in order to strengthen Arendt’s advisory services offering to clients in the areas of Forensic Investigations, Anti-bribery & Corruption, and Corporate Intelligence.
News & Analysis

India: Carlyle Group’s investments in Viyash Life Sciences Private Limited, an integrated generic pharmaceuticals platform

24 November 2021 by L&L Partners

L&L Partners Law Offices advised the Carlyle Group (“Carlyle”), on setting up an integrated generic pharmaceuticals platform, known as Viyash Life Sciences Private Limited in partnership with ex-Mylan senior executive, Dr. Hari Babu Bodepudi and ex- founder of Laurus Labs, Dr. Srihari Raju Kalidindi. L&L has also advised Carlyle on all its follow-on investments into Viyash over a period of time.
News & Analysis

India: Carlyle Group’s generic pharma platform Viyash, invests in Appcure Labs and Appco Pharma LLC

24 November 2021 by L&L Partners

L&L Partners Law Offices advised the Carlyle Group on the acquisition of 100% stake of Appcure Labs Private Limited and the acquisition of majority stake in Appco Pharma LLC through its generic pharma platform, Viyash Life Sciences Private Limited.
Load more